A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Latest Information Update: 05 Aug 2021
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms RAINBOW-Asia
- Sponsors Eli Lilly and Company
- 24 Jun 2021 Primary endpoint (PFS) has been met, according to Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 20 May 2021 Primary endpoint (Overall Survival (OS)) has not been met, according to Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 20 May 2021 Results assessing quality-of-life presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.